Amivantamab-vmjw
Amivantamab-vmjw (pronunciation: am-i-van-tam-ab-vmjw) is a monoclonal antibody designed for the treatment of cancer. It is a bispecific antibody that targets both epidermal growth factor receptor (EGFR) and c-Met.
Etymology
The name "Amivantamab-vmjw" is derived from the International Nonproprietary Names (INN), where "Ami-" refers to the targeting of aminopeptidase, "-vant" is a common stem for monoclonal antibodies, and "-mab" is a common suffix for monoclonal antibodies. The "vmjw" is a unique identifier code.
Usage
Amivantamab-vmjw is used for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy.
Related Terms
- Monoclonal Antibody
- Epidermal Growth Factor Receptor
- c-Met
- Non-Small Cell Lung Cancer
- Chemotherapy
- Mutation
See Also
External links
- Medical encyclopedia article on Amivantamab-vmjw
- Wikipedia's article - Amivantamab-vmjw
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski